Please use this identifier to cite or link to this item:
Title: Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights.
Austin Authors: Noelle, Randolph J;Lines, J Louise;Lewis, Lionel D;Martell, Robert E;Guillaudeux, Thierry;Lee, Sam W;Mahoney, Kathleen M;Vesely, Matthew D;Boyd-Kirkup, Jerome;Nambiar, Dhanya K;Scott, Andrew M 
Affiliation: ImmuNext Inc., Lebanon, NH, United States.;Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, United States.
Department of Microbiology and Immunology, Dartmouth Cancer Center, Geisel School of Medicine at Dartmouth, Hanover, NH, United States.
Section of Clinical Pharmacology, Department of Medicine, Geisel School of Medicine at Dartmouth and Dartmouth Cancer Center, Hanover, NH, United States.
Curis, Inc., Lexington, MA, United States.;Division of Hematology/Oncology, Tufts Medical Center, Boston, MA, United States.
Kineta Inc., Seattle, WA, United States.
Yale University School of Medicine, New Haven, CT, United States.
Department of Medical, Division of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.;Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.
Department of Dermatology, Yale School of Medicine, New Haven, CT, United States.
Hummingbird Bioscience, Houston, TX, United States.
Department of Radiation Oncology, Stanford School of Medicine, Stanford, CA, United States.
Olivia Newton-John Cancer Research Institute and School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia.
Molecular Imaging and Therapy
Issue Date: 2023
Date: 2023
Publication information: Frontiers in Oncology 2023; 13
Abstract: Immune checkpoints limit the activation of the immune system and serve an important homeostatic function but can also restrict immune responses against tumors. Inhibition of specific immune checkpoint proteins such as the B7:CD28 family members programmed cell death protein-1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) has transformed the treatment of various cancers by promoting the anti-tumor activation of immune cells. In contrast to these effects, the V-domain immunoglobulin suppressor of T-cell activation (VISTA) regulates the steady state of the resting immune system and promotes homeostasis by mechanisms distinct from PD-1 and CTLA-4. The effects of VISTA blockade have been shown to include a decrease in myeloid suppression coupled with proinflammatory changes by mechanisms that are separate and distinct from other immune checkpoint proteins; in some preclinical studies these immune effects appear synergistic. Given the potential benefits of VISTA blockade in the context of cancer therapy, the second Annual VISTA Symposium was convened virtually on September 23, 2022, to review new research from investigators and immuno-oncology experts. Discussions in the meeting extended the knowledge of VISTA biology and the effects of VISTA inhibition, particularly on cells of the myeloid lineage and resting T cells, as three candidate anti-VISTA antibodies are in, or nearing, clinical development.
DOI: 10.3389/fonc.2023.1225081
Journal: Frontiers in Oncology
Start page: 1225081
PubMed URL: 37795437
Type: Journal Article
Subjects: PD-1
checkpoint inhibitors (ICIs)
immune checkpoint
immuno-oncology (IO)
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Nov 29, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.